An interventional study of Intracoronary imaging and Angiography in De Novo Large Coronary Vessel, Drug-coated Balloon and Intravascular Ultrasound, sponsored by China National Center for Cardiovascular Diseases. Not yet recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-16.
Sponsored by China National Center for Cardiovascular Diseases · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
A number of 2570 patients scheduled for percutaneous coronary intervention (PCI) with de novo large coronary vessel lesions (reference vessel diameter ≧2.75 mm) suitable for DCB implantation are openly randomized 1:1 to either intracoronary imaging guidance or angiographic guidance groups. The primary objective is to determine whether the IVUS/OCT-guided DCB strategy reduces the incidence of target vessel failure (TVF) at 12 months compared with the coronary angiography (CAG)-guided strategy.
This study is a prospective, multicenter, open-label, randomized controlled trial designed to evaluate the efficacy and safety of IVUS/OCT-guided drug-coated balloon (DCB) strategy compared with a CAG-guided strategy in patients with de novo large coronary vessel lesions (reference vessel diameter ≧2.75 mm). Both groups will follow standardized angiographic safety criteria, with bailout drug-eluting stent (DES) implantation permitted when necessary. In the IVUS/OCT-guided group, lesion assessment, preparation, DCB treatment, and bailout stenting decisions will be optimized according to a predefined IVUS/OCT criterion, whereas the CAG-guided group will undergo treatment primarily based on angiographic assessment.
China National Center for Cardiovascular Diseases is the lead sponsor of 271 studies on the registry; 143 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Participants must meet all of the following three criteria:
Exclusion Criteria:
Participants who meet any of the following conditions are not eligible for inclusion:
1) Chronic total occlusion* 2) Left main coronary artery lesion and left main bifurcation lesion 3) Venous or arterial graft lesion 4) Moderated-Severe tortuous, or severe angulated vessels 6. cardiogenic shock 7. Concurrent medical condition with a of less than 1 year. 8. Known to medications such as Aspirin, Heparin, antiplatelet drugs, or contrast
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
DCB diameter and length will be determined based on Intracoronary imaging measurements, with additional lesion preparation performed at the operator's discretion according to the predefined intravascular imaging optimization criteria.
Procedure: Intracoronary imaging
In the CAG-guided group, DCB treatment will be guided by conventional coronary angiography, with DCB diameter and length determined by visual angiographic assessment.
Procedure: Angiography
In the intracoronary imaging-guided group, lesion preparation will be guided by intravascular imaging findings, with additional balloon dilatation or specialized devices used as needed. Following lesion preparation and DCB treatment, repeat Intracoronary imaging will be performed to assess lumen gain, residual stenosis, dissection morphology, and elastic recoil. The acceptable minimum lumen area (MLA) is ≥ 4.2 mm², with a target optimization criterion of MLA ≥ 70% of the mean reference lumen area. Patients meeting both the intracoronary imaging criteria and angiographic safety criteria will proceed to DCB treatment. If these criteria are not achieved but angiographic safety criteria are satisfied and the patient remains clinically stable, further optimization may be considered. If angiographic safety criteria remain unmet after observation, bailout drug-eluting stent (DES) implantation will be performed.
For patients randomized to the CAG-guided group, the selection of lesion preparation devices, DCB sizing, and the need for bailout stenting will be determined by the operators based on coronary angiographic findings and clinical judgment. Patients meeting the predefined angiographic safety criteria after lesion preparation will proceed to DCB treatment. Bailout drug-eluting stent (DES) implantation will be performed if angiographic safety criteria are not met.
Target vessel failure
Incidence of a composite of cardiac death, target-vessel myocardial infarction and clinically indicated target vessel revascularization
Time frame: 12 months
Device success
* Successful delivery in time and inflation within 30-60 s of the allocated DCB device at the intended target lesion during an attempt with a DCB not previously used (first use) * Successful delivery at the target lesion with final in-device residual stenosis ≤ 30% (DCB) or ≤ 20% (DES) by core laboratory QCA (preferred methodology) or visual assessment * No rescue procedure by stent
Time frame: 0 day (during index PCI)
Procedure success
Device success Freedom from in-hospital TVF
Time frame: 7 days
Periprocedural complications
Incidence of a composite of cardiac death, periprocedural myocardial infarction, acute target lesion/vessel thrombosis, and acute target lesion/vessel occlusion
Time frame: 48 hours
Incidence of cardiac death
Incidence of cardiac death
Time frame: 1, 12, 24, 36, and 60 months
Incidence of target-vessel myocardial infarction
Incidence of target-vessel myocardial infarction
Time frame: 1, 12, 24, 36, and 60 months
Incidence of clinically indicated target vessel revascularization
Incidence of clinically indicated target vessel revascularization
Time frame: 1, 12, 24, 36, and 60 months
Patient-oriented composite endpoint (PoCE)
Incidence of a composite of all-cause mortality, any myocardial infarction, any stroke, and any revascularization
Time frame: 1, 12, 24, 36, and 60 months
all-cause mortality
all-cause mortality
Time frame: 1, 12, 24, 36, and 60 months
Any myocardial infarction
Any myocardial infarction
Time frame: 1, 12, 24, 36, and 60 months
Any stroke
Any stroke
Time frame: 1, 12, 24, 36, and 60 months
Any revascularization
Any revascularization
Time frame: 1, 12, 24, 36, and 60 months
Incidence of net clinical benefit (a composite of cardiac death, target-vessel myocardial infarction, clinically indicated target vessel revascularization and major bleeding)
Incidence of net clinical benefit (a composite of cardiac death, target-vessel myocardial infarction, clinically indicated target vessel revascularization and major bleeding (Bleeding type 3 or 5 according to the Bleeding ARC))
Time frame: 1,12, 24, 36, and 60 months
Incidence of BARC (Bleeding Academic Research Consortium [BARC] definition, type 2,3 or 5)
Incidence of BARC (Bleeding Academic Research Consortium \[BARC\] definition, type 2,3 or 5)
Time frame: 1, 12, 24, 36, and 60 months
Hierarchical composite clinical endpoint of cardiovascular death, TV-MI, and clinically driven TVR
Hierarchical composite clinical endpoint of cardiovascular death, TV-MI, and clinically driven TVR
Time frame: 1, 12, 24, 36 and 60 months
Hierarchical composite clinical endpoint of any death, any stroke, any MI, BARC defined type 3 bleeding events, any revascularization and BARC type 2 bleeding events
Hierarchical composite clinical endpoint of any death, any stroke, any MI, BARC defined type 3 bleeding events, any revascularization and BARC type 2 bleeding events
Time frame: 1, 12, 24, 36 and 60 months
Plan to share: Yes — Deidentified individual participant data that underlie the results reported in the primary publication will be made available to qualified researchers upon reasonable request and approval of a methodologically sound research proposal, subject to an appropriate data use agreement.
Supporting information: Study protocol, Statistical analysis plan
Time frame: Beginning 36 months after publication of the primary study results and continuing for 5 years.
Access criteria: Deidentified individual participant data underlying the results reported in the primary publication will be available to qualified researchers who submit a methodologically sound research proposal. Requests will be reviewed by the study investigators and, where applicable, relevant institutional or ethics authorities. Proposals that substantially overlap with prespecified ongoing analyses may be deferred until completion of those analyses. Data will be provided for the purposes specified in the approved proposal, subject to an appropriate data use agreement and applicable privacy and data protection requirements.
No publications or documents are linked to this record.
Start is estimated for Dec 2026; primary completion for Dec 2028, 24 months later.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
China National Center for Cardiovascular Diseases →